Piper Jaffray Remains Bullish on Horizon Pharma (HZNP) Following 'Strong' Q2, PT Trimmed to $33

August 8, 2016 12:33 PM EDT
Get Alerts HZNP Hot Sheet
Price: $17.08 -0.23%

Rating Summary:
    13 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 22 | Down: 32 | New: 34
Trade HZNP Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Piper Jaffray analyst David Amsellem reiterated an Overweight rating on Horizon Pharma (NASDAQ: HZNP) but trimmed his price target to $33.00 (from $34.00) following "strong" Q2 results. The firm is remaining bullish on the name.

Amsellem commented, "Horizon reported 2Q16 non-GAAP diluted EPS of $0.56 on revenue of $257M, compared to Street estimates of $0.50 and $235M, respectively. Notably, sales from the primary care segment grew by 33% over 2Q15 and by 36% over 1Q16. Even with the recent strength in the shares, we continue to believe that the risk/reward profile for HZNP is attractive at a P/E of 8x our 2017 estimate of $2.66, in the context of strong visibility on a long-term EPS CAGR (2017+) at least in the mid-teens (and this does not reflect any contribution from Actimmune in Friedreich’s ataxia (FA)). We reiterate our Overweight rating and are slightly adjusting our PT to $33 from $34."

For an analyst ratings summary and ratings history on Horizon Pharma click here. For more ratings news on Horizon Pharma click here.

Shares of Horizon Pharma closed at $20.10 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Piper Jaffray

Add Your Comment